{
    "clinical_study": {
        "@rank": "107662", 
        "arm_group": {
            "arm_group_label": "Umbilical Cord Blood + Chemotherapy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Unrelated Cord Blood (UCB) transplant in children is a viable stem cell transplant modality\n      for patients with leukemia and myelodysplasia. UCB is now considered \"Standard Of Care\" in\n      cases where a suitable living bone marrow donor is not available. The survival of UCB is\n      similar to Matched Unrelated Marrow Transplant. This study is considered \"Research\" since\n      UCB is not a licensed product and requires IND. THERE ARE NO SPECIFIC RESEARCH QUESTIONS IN\n      THIS PROTOCOL. This protocol merely provides UCB as a stem cell treatment modality to\n      pediatric patients who may require it after a conditioning regimen that excludes total body\n      irradiation (TBI)."
        }, 
        "brief_title": "Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia", 
        "condition": [
            "Leukemia", 
            "Myelodysplasia", 
            "Acute Lymphocytic Leukemia", 
            "Acute Myelogenous Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The preparative regimen will consist of:\n\n        -  Fludarabine: 25 mg/m2/day IV x 5 doses on Days  -13, to -9\n\n        -  Busulfan 1mg/kg IV every 6 hrs x 16 doses on Days -8 to -5\n\n        -  Melphalan 45 mg/m2/day IV x 3 doses on days -4 to -2\n\n        -  ATGAM 30mg/kg/day x 3 doses on Days -3 to -1\n\n        -  Day 0 will be the day of the UCB Transplant\n\n        -  The GVHD prophylaxis will be Cyclosporin A to maintain level 200-400 beginning on Day\n           -3, through 200-400. Solumedrol at 1mg/kg/day on Day 1 until D+4, then solumedrol\n           2mg/kg/day until Day +19 or till ANC reaches 500/mm2, then taper by 0.2 mg/kg/week."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must be up to 21 years of age\n\n          -  Patients cannot receive total body irradiation (TBI) because of:\n\n               -  Young age  - < 2 years at diagnosis of leukemia resulting in an age < 4 years at\n                  transplantation (due to risk of severe growth retardation and brain damage).\n\n               -  Inability to tolerate TBI because of prior radiation or organ toxicity.\n\n               -  Refractory/multiply relapsed leukemia, for which a traditional\n                  TBI/cyclophosphamide regimen would unlikely lead to a successful outcome.\n\n          -  Patients must have a partially HLA-matched UCB unit.  Unit must be HLA-matched\n             minimally at 4 of 6 HLA-A and B (at intermediate resolution by molecular typing) and\n             DRB1 (at high resolution by molecular typing) loci with the patient. The unit must\n             deliver a pre-cryopreserved nucleated cell dose of at least 2.5 x 10^7 per kilogram.\n\n          -  Acute myelogenous leukemia (AML) at the following stages:\n\n               -  High risk first complete remission (CR1), defined as:\n\n                    -  Having preceding myelodysplasia (MDS)\n\n                    -  High risk cytogenetics (High-risk cytogenetics: del (5q) -5, -7, abn (3q),\n                       t (6;9) complex karyotype (>= 5 abnormalities)\n\n                    -  Requiring > 2 cycles chemotherapy to obtain CR;\n\n               -  Second or greater CR.\n\n               -  First relapse with < 25% blasts in bone marrow.\n\n          -  Patients with therapy-related AML whose prior malignancy has been in remission for at\n             least 12 months.\n\n          -  Acute lymphocytic leukemia (ALL) at the following stages:\n\n          -  High risk first remission, defined as:\n\n               1. Ph+ ALL; or,\n\n               2. MLL rearrangement with slow early response [defined as having M2 (5-25% blasts)\n                  or M3 (>25% blasts on bone marrow examination on Day 14 of induction therapy)];\n                  or,\n\n               3. Hypodiploidy (< 44 chromosomes or DNA index < 0.81); or,\n\n               4. End of induction M3 bone marrow; or,\n\n               5. End of induction M2 with M2-3 at Day 42.\n\n          -  High risk second remission, defined as:\n\n               1. Bone marrow relapse < 36 months from induction; or,\n\n               2. T-lineage relapse at any time; or,\n\n               3. Very early isolated CNS relapse (6 months from diagnosis); or,\n\n               4. Slow reinduction (M2-3 at Day 28) after relapse at any time.\n\n          -  Any third or subsequent CR.\n\n          -  Biphenotypic or undifferentiated leukemia in any CR or if in 1st relapse must have <\n             25% blasts in BM.\n\n          -  MDS at any stage.\n\n          -  Chronic myelogenous leukemia (CML) in chronic or accelerated phase.\n\n          -  All patients with evidence of CNS leukemia must be treated and be in CNS CR to be\n             eligible for study.\n\n          -  Patients \u2265 16 years old must have a Karnofsky score \u2265  70% and patients < 16 years\n             old must have a Lansky score \u2265  70%.\n\n          -  Signed informed consent.\n\n          -  Patients with adequate physical function as measured by:\n\n               1. Cardiac:  Left ventricular ejection fraction at rest must be > 40%, or\n                  shortening fraction > 26%\n\n               2. Hepatic:  Bilirubin \u2264  2.5 mg/dL; and ALT, AST and Alkaline Phosphatase \u2264  5 x\n                  ULN\n\n               3. Renal:  Serum creatinine within normal range for age, or if serum creatinine\n                  outside normal range for age, then renal function (creatinine clearance or GFR)\n                  > 70 mL/min/1.73 m2.\n\n               4. Pulmonary: DLCO, FEV1, FVC (diffusion capacity) > 50% of predicted (corrected\n                  for hemoglobin); if unable to perform pulmonary function tests, then O2\n                  saturation > 92% of room air.\n\n        Exclusion Criteria:\n\n          -  Pregnant (B-positive HCG) or breastfeeding.\n\n          -  Evidence of HIV infection or HIV positive serology.\n\n          -  Current uncontrolled bacterial, viral or fungal infection (currently taking\n             medication and progression of clinical symptoms).\n\n          -  Autologous transplant < 6 months prior to enrollment.\n\n          -  Prior autologous transplant for the disease for which the UCB transplant will be\n             performed.\n\n          -  Allogeneic hematopoietic stem cell transplant < 6 months prior to enrollment.\n\n          -  Active malignancy other than the one for which the UCB transplant is being performed\n             within 12 months of enrollment\n\n          -  Active CNS leukemia.\n\n          -  Requirement of supplemental oxygen.\n\n          -  HLA-matched related donor able to donate."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007863", 
            "org_study_id": "UMIAMI-20080774"
        }, 
        "intervention": [
            {
                "arm_group_label": "Umbilical Cord Blood + Chemotherapy", 
                "description": "Following the administration of the preparative therapy, all subjects will undergo UCB transplantation.  Umbilical Cord Blood Transfusion will occur on Day 0", 
                "intervention_name": "Umbilical Cord Blood Transfusion", 
                "intervention_type": "Procedure", 
                "other_name": "UCB"
            }, 
            {
                "arm_group_label": "Umbilical Cord Blood + Chemotherapy", 
                "description": "Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -13 through -9 for a total of 5 doses.  Fludarabine will not be dose adjusted for body weight.", 
                "intervention_name": "Fludarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Umbilical Cord Blood + Chemotherapy", 
                "description": "Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.", 
                "intervention_name": "Busulfan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Umbilical Cord Blood + Chemotherapy", 
                "description": "Melphapan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days -4 through -2 for a total of 3 doses.", 
                "intervention_name": "Melphalan", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Busulfan", 
                "Melphalan", 
                "Fludarabine monophosphate", 
                "Fludarabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Leukemia", 
            "Myelodysplasia", 
            "Acute lymphocytic leukemia", 
            "ALL", 
            "Acute myelogenous leukemia", 
            "AML", 
            "Pediatric"
        ], 
        "lastchanged_date": "December 6, 2013", 
        "location": [
            {
                "contact": {
                    "email": "MAndreasky@med.miami.edu", 
                    "last_name": "Martin Andreansky, MD, PhD", 
                    "phone": "305-243-0850"
                }, 
                "contact_backup": {
                    "email": "sylvester@emergingmed.com", 
                    "last_name": "University of Miami Sylvester Comprehensive Cancer Center", 
                    "phone": "866-574-5124"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami Sylvester Comprehensive Cancer Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Martin Andreansky, MD,PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Julio Barredo, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ofelia Alvarez, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Joanna Davis, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Cristina Fernandes, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "John Goldberg, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Antonello Podda, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Gary Kleiner, MD. PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "SShariat@med.miami.edu", 
                    "last_name": "Sherry Shariatmadar, MD", 
                    "phone": "305-585-6467"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Jackson Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "Sherry Shariatmadar, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Treatment Protocol: Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia Using Conditioning Regimen Without Radiation", 
        "overall_official": {
            "affiliation": "University of Miami Sylvester Comprehensive Cancer Center", 
            "last_name": "Martin Andreasky, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Unrelated Cord Blood (UCB) transplant in children is a viable stem cell transplant modality for patients with leukemia and myelodysplasia. UCB is now considered \"Standard Of Care\" in cases where a suitable living bone marrow donor is not available. The survival of UCB is similar to Matched Unrelated Marrow Transplant. This study is considered \"Research\" since UCB is not a licensed product and requires IND. THERE ARE NO SPECIFIC RESEARCH QUESTIONS IN THIS PROTOCOL. This protocol merely provides UCB as a stem cell treatment modality to pediatric patients who may require it after a conditioning regimen that excludes Total Body Irradiation.", 
            "measure": "Number of Patients Responding to Umbilical Cord Blood Therapy Using Conditioning Regimen Without Radiation", 
            "safety_issue": "No", 
            "time_frame": "2 Years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007863"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Miami Sylvester Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Miami Sylvester Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2008", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}